Table 3.
Standardized Cumulative Incidence of Cardiovascular Events in Medically Treated Primary Aldosteronism and Essential Hypertension.
| Primary Aldosteronism |
Essential Hypertension |
Difference in Cumulative Incidence |
|
|---|---|---|---|
| 3-Year Cumulative Incidence (per 100 persons) | |||
| Unadjusted (95% CI) | 16·9 (14·7, 19·1) | 8·6 (8·3, 8·9) | 8·3 (6·1, 10·5) |
| Adjusted (95% CI)a | 15·3 (13·2, 17·4) | 8·7 (8·4, 9·0) | 6·6 (4·5, 8·6) |
| 5-Year Cumulative Incidence (per 100 persons) | |||
| Unadjusted (95% CI) | 25·6 (22·5, 28·7) | 13·4 (13·1, 13·7) | 12·2 (9·1, 15·3) |
| Adjusted (95% CI)a | 23·0 (20·2, 25·8) | 13·5 (13·2, 13·8) | 9·5 (6·6, 12·3) |
| 10-Year Cumulative Incidence (per 100 persons) | |||
| Unadjusted (95% CI) | 42·4 (37·9, 46·9) | 23·6 (23·1, 24·1) | 18·8 (14·3, 23·3) |
| Adjusted (95% CI)a | 38·1 (34·2, 42·0) | 24·0 (23·5, 24·5) | 14·1 (10·1, 18·0) |
a
Standardized to the distributions at the time of study entry in our cohort for the following variables: age, sex, race/ethnicity, BMI, smoking status, diabetes mellitus, hemoglobin A1C, atrial fibrillation, LDL cholesterol, statin use, daily aspirin use, estimated glomerular filtration rate, systolic blood pressure, diastolic blood pressure, and number of antihypertensive medications.